SCHEMBL23924907

SCHEMBL23924907

COc1cc(C=O)cc2ccoc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
HPGD P15428 3/20 0.49
TSHR P16473 2/20 0.49
TRIM24 O15164 1/20 0.49
ALDH5A1 P51649 1/20 0.49
ABAT P80404 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
CYP3A4 P08684 2/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP2A6 P11509 2/20 0.46
AOX1 Q06278 1/20 0.45
FDPS P14324 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30287152 0.89 CYP2A6 (0.42) ALDH1A1HPGDTSHRTRIM24ALDH5A1
SCHEMBL5686717 0.76 TUBB1 (0.64) TTR
SCHEMBL5686721 0.76 TUBB1 (0.64) TTR
SCHEMBL5686732 0.76 TUBB1 (0.64) TTR
SCHEMBL5150242 0.76 ALDH1A1 (0.45) ALDH1A1HPGDCYP3A4LMNAKDM4E
SCHEMBL31141575 0.75 CYP2A6 (0.52) ALDH1A1TSHRTRIM24TRIM33CYP3A4
SCHEMBL7483940 0.75 KDM4E (0.47) ALDH1A1HPGDTSHRCYP3A4LMNA
SCHEMBL806505 0.75 ALDH1A1 (0.47) ALDH1A1HPGDTSHRCYP3A4LMNA
SCHEMBL119906 0.75 CYP3A4 (0.47) ALDH1A1HPGDTSHRTDP1CYP3A4
SCHEMBL23924892 0.75 CYP2A6 (0.52) ALDH1A1HPGDTRIM24ALDH5A1ABAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270210-A1 BCL-2 Inhibitor BEIGENE, LTD. (KY) 2025-08-28 US disclosed
US-12286430-B2 Bcl-2 inhibitor BEIGENE, LTD. (KY) 2025-04-29 US disclosed
US-20240376097-A1 BCL-2 Inhibitor BEIGENE LTD. (KY) 2024-11-14 US disclosed
CN-116969937-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116969936-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116802179-A BCL-2 inhibitors 百济神州有限公司 2023-09-22 CN disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed
EP-4136084-A1 BCL-2 INHIBITOR BeiGene, Ltd. (KY) 2023-02-22 EP disclosed
WO-2021208963-A1 BCL-2 INHIBITOR BEIGENE, LTD. (KY) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270210-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 ALDH1A1 2918/4885HPGD 2735/4885TSHR 4278/4885
US-20230159522-A1 BCL-2 INHIBITOR BCL2, BCL2A1, BCL2L1 ALDH1A1 2918/4885HPGD 2735/4885TSHR 4278/4885
US-20240376097-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 ALDH1A1 2918/4885HPGD 2735/4885TSHR 4278/4885
US-12286430-B2 Bcl-2 inhibitor BCL2, BCL2A1, BCL2L1 ALDH1A1 2918/4885HPGD 2735/4885TSHR 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.